IL31 and Alzheimer disease: [20] In acute lesions, the activation of Th2 (IL-4, IL-5, IL-13, IL-31, and CCL18) and Th22 (IL-22 and S100A proteins) pathways down-regulates terminal differentiation genes and tight junction products, contributing to the skin barrier defect in AD.